Dare Bioscience (DARE) Set to Post Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Dare Bioscience to post earnings of ($0.1267) per share and revenue of $2.04 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, analysts expect Dare Bioscience to post ($0.74) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Dare Bioscience Stock Performance

DARE opened at $0.66 on Thursday. The stock’s fifty day moving average is $0.74 and its 200-day moving average is $1.55. Dare Bioscience has a one year low of $0.62 and a one year high of $3.78. The company has a market capitalization of $13.02 million, a PE ratio of -0.95 and a beta of 1.11.

Analysts Set New Price Targets

A number of research firms recently commented on DARE. UBS Group set a $1.00 target price on shares of Dare Bioscience in a report on Monday, September 14th. HC Wainwright restated a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Benchmark reissued a “buy” rating on shares of Dare Bioscience in a research note on Monday, August 17th. Weiss Ratings downgraded Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Finally, LADENBURG THALM/SH SH began coverage on Dare Bioscience in a report on Monday, October 26th. They set a “buy” rating and a $2.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Dare Bioscience Company Profile

Daré Bioscience, Inc (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies.

Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older.